| Course | HCR 564 Global Regulatory Affairs Leadership |
|---|---|
| Module | Module 4 |
| Paper type | Critical analysis paper |
| Length | About 671 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 564 Module 4
Faster, Wider, Smarter? A Critique of Three Developments Reshaping Global Therapeutics
Student Name
MS in Regulatory Science, Arizona State University
HCR 564: Global Regulatory Affairs Leadership
Instructor Name
Month Day, Year
Faster, Wider, Smarter? A Critique of Three Developments Reshaping Global Therapeutics
Introduction
The global therapeutics industry is being reshaped less by any single scientific breakthrough than by changes in how evidence is generated and how regulators work together. Three developments stand out: collaborative regulatory review across countries, the use of real-world evidence in decisions and artificial intelligence across the product life cycle. Each promises speed or reach. This paper critiques each by asking what it delivers, what it risks and who benefits.
Development 1: Collaborative and Reliance-Based Review
In 2019, the FDA's Oncology Center of Excellence launched Project Orbis, under which the FDA and partner regulators review promising cancer applications at the same time. In its first year, the program received 60 marketing applications and produced 38 approvals, with partner submissions arriving a median of 0.6 months after the FDA's, while each country kept full authority over its own decision (de Claro et al., 2020).
Critique: The promise is real for patients in smaller markets, who historically waited years after U.S. approval. The risk is quieter. If partners rely heavily on the FDA's assessment, the world loses independent second opinions, and errors propagate. Reliance also favors applications that sponsors choose to file early in many countries, which are often high-priced oncology drugs, leaving older or less profitable medicines outside the fast lane.
Development 2: Real-World Evidence
Real-world evidence (RWE) is evidence about a medical product's use, benefits or risks drawn from data collected outside traditional trials, such as health records, claims and registries. The FDA has used RWE for safety monitoring for years and increasingly considers it for effectiveness in specific circumstances, such as external control arms for rare diseases and label expansions (Concato & Corrigan-Curay, 2022).
Critique: RWE can answer questions trials cannot, about older, sicker and more diverse patients and about long-term outcomes. But observational data carry confounding and missing information that randomization prevents, and the same flexibility that makes RWE attractive makes it easy to choose analyses that favor a desired result. The future depends on prespecified protocols, transparent data provenance and regulators with the analytic capacity to audit them.
Development 3: Artificial Intelligence
Artificial intelligence is being applied across development: predicting molecular properties, selecting trial sites and patients, analyzing images and adverse event reports and drafting regulatory documents. The FDA has issued draft guidance on how sponsors should establish the credibility of AI models used to support regulatory decisions, organized around the model's context of use and the risk if it is wrong (U.S. Food and Drug Administration, 2025).
Critique: AI could shorten discovery and reduce the cost of trials. Its risks are opacity, bias inherited from training data and overconfidence in predictions that have not been validated prospectively. In regulation specifically, AI that drafts or summarizes submissions could speed review but could also obscure errors no one checks. The credibility framework is a sound start; enforcement will matter more than principles.
Common Threads
All three trade some traditional assurance for speed or scope. None is inherently good or bad; each requires regulators to invest in new capabilities rather than simply accept faster answers.
| Development | Main benefit | Main risk | What leaders should require |
|---|---|---|---|
| Collaborative review | Faster access in smaller markets | Loss of independent judgment | Transparent assessment reports and retained national authority |
| Real-world evidence | Answers for patients trials exclude | Confounding and selective analysis | Prespecified protocols and data provenance |
| Artificial intelligence | Speed and lower cost | Opacity and bias | Context-of-use validation and human review |
Implications for Regulatory Leadership
Regulatory leaders in industry should resist treating these developments as shortcuts. A company that uses RWE or AI should welcome scrutiny of its methods, and one that benefits from collaborative review should support transparent publication of assessments. Regulators, for their part, need staff who can audit data and algorithms, not only read trial reports.
Conclusion
Collaborative review, real-world evidence and artificial intelligence can make therapeutics reach more patients sooner. Whether they also make them safer depends on the same old virtues, independent judgment, transparent methods and validated evidence, applied to new tools.
References
Concato, J., & Corrigan-Curay, J. (2022). Real-world evidence: Where are we now? New England Journal of Medicine, 386(18), 1680-1682. https://doi.org/10.1056/NEJMp2200089
de Claro, R. A., Spillman, D., Hotaki, L. T., Shum, M., Mouawad, L. S., Santos, G. M. L., Robinson, K., Hunt, M., Healy, C., Chan, A., Looi, Y. H., Rodrigues, C., Rohr, U.-P., Walther, C., & Pazdur, R. (2020). Project Orbis: Global collaborative review program. Clinical Cancer Research, 26(24), 6412-6416. https://doi.org/10.1158/1078-0432.CCR-20-3292
U.S. Food and Drug Administration. (2025). Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products [Draft guidance for industry]. https://www.fda.gov/media/184830/download
HCR 564 Module 4 instructions, in plain terms
HCR 564's Paper 1 is worth 15% of the course grade and follows the modules on global regulatory affairs, harmonization, transparency and early access. The syllabus asks for a critique of future developments in the global therapeutics industry, with full instructions in Canvas. A critique is not a forecast or a list of trends; it evaluates developments that are already under way, weighing what they promise against what they risk and for whom. Choose two to four developments you can support with evidence, such as collaborative review, reliance between regulators, real-world evidence, artificial intelligence, decentralized trials, early access programs or patient-focused drug development, and connect them to the course's themes. Because this is a leadership course, closing with what regulatory leaders should do gives the critique a practical edge. The second paper, a personal leadership development plan, comes later in the course.
How the HCR 564 Module 4 example is put together
The sample opens by naming three developments and the question it will ask of each. For each development the paper first describes it with evidence, for instance a review program's first-year results, then critiques it by weighing benefit against risk. A table then compares the three on main benefit, main risk and what leaders should require, followed by a short paragraph on the common thread. An implications section speaks to regulatory leaders in industry and agencies, and the conclusion restates the paper's judgment in two sentences. Each development section follows the same two-part pattern, which makes the three easy to compare.
Reading the HCR 564 Module 4 grading rubric
Paper 1 counts for 15% of the HCR 564 grade. A strong critique chooses developments that are real and significant, describes each accurately with evidence, evaluates benefits and risks for patients, regulators and industry, connects to course themes such as harmonization and transparency and reaches a clear judgment with practical implications. Points are lost when the paper describes trends without critique, when claims rest on press releases or vendor marketing, when risks are ignored and when the paper lists many developments superficially. Readers in a leadership course value papers that end with what leaders should do, since critique without direction is of limited use to a regulatory professional.
HCR 564 Module 4 help from the desk
Choose two to four developments, not ten. For each, find one strong source describing it and one point of evidence about its effects. Write a critique paragraph that weighs benefits and risks for named stakeholders. Use a comparison table to show common threads. Link each development to a course module. End with recommendations for leaders. Avoid futurist speculation without evidence. If you are unsure which developments have enough evidence, the desk can suggest current sources. Write the critique paragraph for each development before you write its description, so the description includes only what the critique needs. Name the stakeholders who gain and lose in each case. Keep your recommendations to what a regulatory leader could actually do in an organization.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 564 and MS in Regulatory Science sample papers
- HCR 579 Module 5: Annotated Bibliography: Patient-Derived Organoids
- HCR 563 Module 4: Assignment 2: Building Quality Into Clinical Trials
- HCR 543 Module 7: Summative Evaluation Paper: Emerging Food Safety Issues
- HCR 544 Module 7: Food Safety Individual Project Paper
HCR 564 Module 4 questions, answered
Where can I find a free HCR 564 Module 4 sample paper?
This page has a full HCR 564 Paper 1 sample critiquing collaborative review, real-world evidence and artificial intelligence in global therapeutics.
What is Project Orbis?
An FDA-led program, launched in 2019, in which partner regulators review promising cancer applications at the same time while keeping their own decisions.
What is real-world evidence?
Evidence about a product's use, benefits or risks from data gathered outside traditional trials, such as health records, claims and registries.
How should a critique of industry developments be structured?
Describe each development with evidence, weigh its benefits and risks for named stakeholders and end with practical implications.
How much is HCR 564 Paper 1 worth?
15% of the course grade; the second paper, a leadership development plan, is worth 25%.